Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cumberland Pharmaceuticals (CPIX) Cash from Discontinued Operations (2019 - 2021)

Cumberland Pharmaceuticals' Cash from Discontinued Operations history spans 3 years, with the latest figure at 503318.0 for Q4 2021.

  • For Q4 2021, Cash from Discontinued Operations fell 62.78% year-over-year to 503318.0; the TTM value through Sep 2022 reached 503318.0, down 82.3%, while the annual FY2021 figure was 1994322.0, 43.31% down from the prior year.
  • Cash from Discontinued Operations for Q4 2021 was 503318.0 at Cumberland Pharmaceuticals, up from 496787.0 in the prior quarter.
  • Across five years, Cash from Discontinued Operations topped out at 3027800.0 in Q4 2019 and bottomed at 38567.0 in Q2 2020.
  • The 3-year median for Cash from Discontinued Operations is 648983.5 (2020), against an average of 918680.0.
  • The largest annual shift saw Cash from Discontinued Operations plummeted 97.11% in 2020 before it soared 1193.35% in 2021.
  • A 3-year view of Cash from Discontinued Operations shows it stood at 3027800.0 in 2019, then tumbled by 55.34% to 1352156.0 in 2020, then crashed by 62.78% to 503318.0 in 2021.
  • Per Business Quant, the three most recent readings for CPIX's Cash from Discontinued Operations are 503318.0 (Q4 2021), 496787.0 (Q3 2021), and 498807.0 (Q2 2021).